PL2493466T3 - Nowe przeciwguzowe zastosowanie kabazytakselu - Google Patents

Nowe przeciwguzowe zastosowanie kabazytakselu

Info

Publication number
PL2493466T3
PL2493466T3 PL10782039T PL10782039T PL2493466T3 PL 2493466 T3 PL2493466 T3 PL 2493466T3 PL 10782039 T PL10782039 T PL 10782039T PL 10782039 T PL10782039 T PL 10782039T PL 2493466 T3 PL2493466 T3 PL 2493466T3
Authority
PL
Poland
Prior art keywords
cabazytaxel
tumble
application
new anti
new
Prior art date
Application number
PL10782039T
Other languages
English (en)
Inventor
Sunil Gupta
Original Assignee
Sanofi Mature Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2493466(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Mature Ip filed Critical Sanofi Mature Ip
Publication of PL2493466T3 publication Critical patent/PL2493466T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
PL10782039T 2009-10-29 2010-10-27 Nowe przeciwguzowe zastosowanie kabazytakselu PL2493466T3 (pl)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US25616009P 2009-10-29 2009-10-29
US29390310P 2010-01-11 2010-01-11
US35583410P 2010-06-17 2010-06-17
US35588810P 2010-06-17 2010-06-17
US36992910P 2010-08-02 2010-08-02
US38393310P 2010-09-17 2010-09-17
US38996910P 2010-10-05 2010-10-05
EP10782039.1A EP2493466B1 (en) 2009-10-29 2010-10-27 Novel antitumoral use of cabazitaxel
PCT/IB2010/054866 WO2011051894A1 (en) 2009-10-29 2010-10-27 Novel antitumoral use of cabazitaxel

Publications (1)

Publication Number Publication Date
PL2493466T3 true PL2493466T3 (pl) 2021-11-15

Family

ID=43567614

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10782039T PL2493466T3 (pl) 2009-10-29 2010-10-27 Nowe przeciwguzowe zastosowanie kabazytakselu

Country Status (31)

Country Link
US (8) US8927592B2 (pl)
EP (1) EP2493466B1 (pl)
JP (2) JP5566466B2 (pl)
KR (1) KR101712231B1 (pl)
CN (1) CN102770131A (pl)
AR (1) AR078824A1 (pl)
AU (4) AU2010310986A1 (pl)
BR (1) BR112012011457A2 (pl)
CA (1) CA2779009A1 (pl)
CR (1) CR20120204A (pl)
DK (1) DK2493466T3 (pl)
EA (1) EA024186B1 (pl)
EC (1) ECSP12011836A (pl)
ES (1) ES2862340T3 (pl)
GT (1) GT201200123A (pl)
IL (3) IL219443A0 (pl)
MA (1) MA33767B1 (pl)
MX (1) MX336339B (pl)
MY (1) MY164086A (pl)
NI (1) NI201200071A (pl)
PE (1) PE20121429A1 (pl)
PH (1) PH12012500848A1 (pl)
PL (1) PL2493466T3 (pl)
PT (1) PT2493466T (pl)
SG (1) SG10201810928SA (pl)
SV (1) SV2012004192A (pl)
TN (1) TN2012000188A1 (pl)
TW (2) TWI654975B (pl)
UY (1) UY32987A (pl)
WO (1) WO2011051894A1 (pl)
ZA (1) ZA201203123B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
KR101712231B1 (ko) 2009-10-29 2017-03-03 아벤티스 파마 소시에떼아노님 카바지탁셀의 신규한 항종양 용도
WO2012142117A1 (en) * 2011-04-12 2012-10-18 Plus Chemicals Sa Solid state forms of cabazitaxel and processes for preparation thereof
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
EP2791122B1 (en) 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
US9403785B2 (en) * 2012-01-03 2016-08-02 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
EP2880021A4 (en) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd AMORPHIC CABACITAXEL
TW201827417A (zh) * 2013-03-04 2018-08-01 法商安萬特醫藥公司 卡巴他賽(cabazitaxel)及其治療轉移性前列腺癌之用途
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
JP6841772B2 (ja) * 2015-02-17 2021-03-10 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 前立腺癌の処置におけるカバジタキセルの使用
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3509569A1 (en) 2016-09-07 2019-07-17 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US10195214B2 (en) * 2017-03-01 2019-02-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
US20210088505A1 (en) * 2017-04-07 2021-03-25 La Jolla Institute For Allergy And Immunology Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof
US20250017891A1 (en) * 2023-07-04 2025-01-16 Twi Pharmaceuticals, Inc. Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
FR2732340B1 (fr) 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
IL141231A0 (en) 1998-08-20 2002-03-10 Aventis Pharma Sa New use of taxoid derivatives
US6403634B1 (en) 1999-01-13 2002-06-11 Aventis Pharma S.A. Use of taxoid derivatives
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
DE50301051D1 (de) 2003-07-02 2005-09-29 Scheuten Glasgroep Venlo Verfahren zur Herstellung einer Brandschutzverglasung
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN102605066A (zh) 2004-12-08 2012-07-25 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
EP1700596A1 (en) 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (en) * 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201171195A8 (ru) 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
WO2011034954A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. Treatment of cancer
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
KR101712231B1 (ko) 2009-10-29 2017-03-03 아벤티스 파마 소시에떼아노님 카바지탁셀의 신규한 항종양 용도
US8686165B2 (en) 2009-11-04 2014-04-01 Emcure Pharmaceuticals Limited Process for preparation of taxane derivatives
CN102781237A (zh) 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
EP2556166A1 (en) 2010-04-08 2013-02-13 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011130317A2 (en) 2010-04-13 2011-10-20 Amplyx Pharmaceuticals Inc. Therapeutic agents having reduced toxicity
EP2558109A4 (en) 2010-04-16 2014-09-24 Bellicum Pharmaceuticals Inc METHOD FOR TREATING HARD TUMORS
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Also Published As

Publication number Publication date
AR078824A1 (es) 2011-12-07
IL219443A0 (en) 2012-06-28
JP5566466B2 (ja) 2014-08-06
TWI654975B (zh) 2019-04-01
DK2493466T3 (da) 2021-04-26
MX2012005030A (es) 2012-12-05
US20190151278A1 (en) 2019-05-23
JP6182510B2 (ja) 2017-08-16
TW201127374A (en) 2011-08-16
EA024186B1 (ru) 2016-08-31
ZA201203123B (en) 2013-06-26
KR20120093986A (ko) 2012-08-23
SV2012004192A (es) 2012-08-23
MA33767B1 (fr) 2012-11-01
EP2493466B1 (en) 2021-03-10
PE20121429A1 (es) 2012-11-06
TW201611831A (en) 2016-04-01
CN102770131A (zh) 2012-11-07
AU2017232227B2 (en) 2019-06-06
US8927592B2 (en) 2015-01-06
AU2016200598A1 (en) 2016-02-25
MX336339B (es) 2016-01-14
US20120301425A1 (en) 2012-11-29
KR101712231B1 (ko) 2017-03-03
US20210169843A1 (en) 2021-06-10
ECSP12011836A (es) 2012-07-31
EA201270606A1 (ru) 2013-01-30
AU2017232227A1 (en) 2017-10-12
PH12012500848A1 (en) 2016-02-08
BR112012011457A2 (pt) 2016-05-03
SG10201810928SA (en) 2019-01-30
CA2779009A1 (en) 2011-05-05
GT201200123A (es) 2013-11-07
JP2013509394A (ja) 2013-03-14
US10583110B2 (en) 2020-03-10
EP2493466A1 (en) 2012-09-05
JP2014196323A (ja) 2014-10-16
NI201200071A (es) 2012-08-20
PT2493466T (pt) 2021-03-29
US20150118182A1 (en) 2015-04-30
US20180125810A1 (en) 2018-05-10
US10716777B2 (en) 2020-07-21
ES2862340T3 (es) 2021-10-07
MY164086A (en) 2017-11-30
UY32987A (es) 2011-05-31
US12453712B2 (en) 2025-10-28
TN2012000188A1 (en) 2013-12-12
TWI533866B (zh) 2016-05-21
AU2010310986A1 (en) 2012-06-14
IL267583A (en) 2019-08-29
IL250254A0 (en) 2017-03-30
US20240139146A1 (en) 2024-05-02
WO2011051894A1 (en) 2011-05-05
US20150104411A1 (en) 2015-04-16
US20200155497A1 (en) 2020-05-21
AU2019203514A1 (en) 2019-06-06
CR20120204A (es) 2012-07-04

Similar Documents

Publication Publication Date Title
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
SMT201600075B (it) Composto di diamminocarbossammide eterociclica
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
IL225867B (en) Coelenterazine substrates
EP2414948A4 (en) APPLICATION SHARING
PT2506716T (pt) Novos compostos tricíclicos
EP2518066A4 (en) NOVEL THROMBOCYTE AGGREGATION INHIBITOR
BR112012000657A2 (pt) novos azabicilohexanos
FI20095529L (fi) Probioottien uusi käyttö
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
UY33156A (es) Nuevos compuestos tienopirrol
DK2453858T3 (da) Fremgangsmåde
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
LT2506840T (lt) Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
DOP2011000348A (es) Construcciones casb7439
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
DK2173197T3 (da) Fremgangsmåde
EP2595966A4 (en) SYNTHESIS OF CYCLOPENTACHINAZOLINES
IT1400080B1 (it) Disposizione di esca
FR2956419B1 (fr) Elements de construction calorifuges
FR2955136B1 (fr) Arret de vantail
FI9141U1 (fi) Apuväline
AT508508A3 (de) Heuballenbohrer
UY33133A (es) Nuevos derivados de piridazina
UA21042S (uk) Комплект бланків